Phase III Trial Shows Crizotinib Superior to Single-Agent Chemotherapy for ALK-Positive Lung Cancer

The results of a new Phase III trial show that crizotinib, a targeted therapy, is a more effective treatment than standard chemotherapy for patients with advanced, ALK-positive lung cancer, researchers said.
Medical Xpress